{"links":{"html":"https://www.erudio.com/reports/laser301-nct04248829","json":"https://www.erudio.com/reports/laser301-nct04248829.json","markdown":"https://www.erudio.com/reports/laser301-nct04248829.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"laser301-04248829"}},"request":"https://www.erudio.com/contact?report=laser301-04248829"},"offer":{"cited_commentary_sources":18,"verified_hcp_statements":88,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":15,"optional":true,"price_per_verified_person_usd":15,"price_usd":225,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"laser301-nct04248829"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=laser301-04248829","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/laser301-nct04248829","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T03:58:12.712733Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":4,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":20,"coverage":"discussed","id":"A1","source_count":5,"title":"Direct comparison with osimertinib and contribution of components"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":6,"title":"CNS activity, monitoring and the clinical pattern of progression"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":1,"title":"L858R-specific choice and a proposed biologic edge"},{"claim_count":9,"coverage":"discussed","id":"A4","source_count":3,"title":"Access, price, earlier-line opportunity and patient reassurance"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":4,"title":"Monotherapy versus first-line intensification: benefit, burden and shared choice"},{"claim_count":5,"coverage":"discussed","id":"A6","source_count":2,"title":"Resistance, sequencing and preservation of later-line options"},{"claim_count":5,"coverage":"discussed","id":"A7","source_count":1,"title":"Rapid testing, immunotherapy deferral and urgent chemotherapy"}],"counts":{"cited_sources":22,"claims_by_expression_type":{"comparison":20,"experience":4,"interpretation":19,"opinion":21,"primary_context":10,"question":4,"restatement":6,"uncertainty":2,"unspecified":2},"claims_by_kind":{"objective_result":2,"protocol_statement":8,"source_observation":78},"clinician_statements":47,"evidence_units":67,"findings":10,"organisational_accounts":2,"people_cited":20,"people_identity_verified":15,"people_total":20,"screened_sources":48,"verified_claims":88},"findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":0,"views":6},"has_counterview":true,"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":5,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"A positive trial against gefitinib still leaves a contested contemporary comparator"},{"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":6,"experience":0,"questions":3,"restated":0,"views":5},"has_counterview":true,"limitations":2,"links":{"context":1,"support":15},"ma_question":true,"named_voices":8,"passages":13,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"An osimertinib-like alternative is a recurrent interpretation, not demonstrated superiority or equivalence"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":0,"views":2},"has_counterview":true,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":5,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"A subtype-based L858R preference is expressed strongly, but its explanation remains hypothetical"},{"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":4,"experience":0,"questions":0,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":4,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Different toxicity profiles motivate conditional choice, not a blanket safety ranking"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":5,"passages":8,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"publication":1}},"title":"CNS activity elicits enthusiasm without eliminating surveillance or evidentiary limits"},{"id":"F6","structure":{"claims":8,"claims_by_group":{"comparisons":3,"experience":1,"questions":0,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":5,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Earlier access, affordability and reassurance contribute to perceived clinical value"},{"id":"F7","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":3,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"First-line intensification is framed as a benefit–burden and shared-decision question"},{"id":"F8","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"Overall survival and the pattern of progression may matter beyond the PFS interval"},{"id":"F9","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"An upfront choice may alter resistance and consume a preferred later-line option"},{"id":"F10","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Testing supports immunotherapy deferral, with an explicit urgent-treatment exception"}],"medical_affairs_question":"What evidence would justify choosing an additional monotherapy option or intensifying treatment for a particular patient, after accounting for subtype uncertainty, CNS risk, tolerability, access and the subsequent treatment pathway?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Positive against gefitinib; contested relevance of the comparator"},{"id":"section-2","level":2,"title":"Similar-looking monotherapies, with different levels of comparative evidence"},{"id":"section-3","level":2,"title":"A proposed L858R distinction challenges the broadly similar reading"},{"id":"section-4","level":2,"title":"Toxicity differences support individualized choice, with important qualifications"},{"id":"section-5","level":2,"title":"CNS enthusiasm does not imply guaranteed control"},{"id":"section-6","level":2,"title":"Access and patient support are part of the perceived benefit"},{"id":"section-7","level":2,"title":"Intensification: benefit, burden and reasons not to add treatment"},{"id":"section-8","level":2,"title":"Survival and the consequences of progression may change the choice"},{"id":"section-9","level":2,"title":"The initial regimen affects the question asked of later-line treatment"},{"id":"section-10","level":2,"title":"Molecular work-up: defer immunotherapy when possible, but preserve urgent care"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment"},{"findings":[{"id":"F5","shared_claims":3},{"id":"F8","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":8},{"id":"F7","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T03:58:12.712733Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T04:08:57Z","record_hash":"8bd8291f9af29e5c7fbb3a6a2fcf9e65a5f64929b1c2eec793f4f47bcfb3b8ac","release_hash":"c6178e9a2c231dea479a9eff9459154cf92a35d9b543fb6b81bbd1b73ac68ca0","report_id":"erudio-nct04248829","run_id":"88a2f948-a928-4a25-901b-bb591538422b","schema_version":"5.0","slug":"laser301-04248829","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"LASER301 asks whether first-line lazertinib delays progression compared with gefitinib in previously untreated patients with advanced non-small-cell lung cancer harboring sensitizing EGFR mutations. Commentary comes from X and LinkedIn posts and podcasts, including a medical oncologist. The discussion turns on gefitinib’s contested relevance as a comparator, whether lazertinib offers an alternative to osimertinib rather than an advance, and how toxicity makes selection between the drugs conditional.","meta_description":"48 sources screened · 88 verified statements (47 from clinicians verified by NPI or staff page) from 22 sources · 10 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-cc77b1903c3f7821d0e6","claim-47b07a53bb9f6d927b52"],"id":"F2","paraphrase":"An X thread asked whether lazertinib improves clinical outcomes relative to osimertinib.","publication_caveats":{"reason":"Source-specific publication caveats are not stated.","status":"not_set"},"source_channel":"x_thread","source_date":"2022-12-03","title":"An osimertinib-like alternative is a recurrent interpretation, not demonstrated superiority or equivalence"},{"cited_claim_ids":["claim-c1aaa03b4b41b65f37aa","claim-08a14996008abbb86f77"],"id":"F3","paraphrase":"An X exchange asked how adding chemotherapy to osimertinib might affect its comparison with lazertinib in L858R disease.","publication_caveats":{"reason":"Source-specific publication caveats are not stated.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-01-16","title":"A subtype-based L858R preference is expressed strongly, but its explanation remains hypothetical"}]},"publication":{"approved_at":"2026-10-31T04:08:57Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":48},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on immature overall survival evidence when weighing first-line treatment options for advanced EGFR-mutated lung cancer.","Not yet captured in this edition: a view on first-line combination treatment and expectations for immature overall survival evidence.","Not yet captured in this edition: a question about combining amivantamab with osimertinib rather than lazertinib in first-line EGFR-mutated advanced lung cancer.","Not yet captured in this edition: a view on tentative cross-trial efficacy comparisons as a rationale for first-line treatment enthusiasm.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","119 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report describes the sources reviewed for this edition, not all HCPs or all public discussion; source totals and repeated posts cannot be interpreted as independent-clinician counts.","Some passages have not been fully assessed for clinical views, including portions of the a podcast episode published on 3 August 2024. Coverage of that episode does not support a complete account of its resistance rationale, administration-route preferences, early efficacy–toxicity appraisal or tentative cross-trial calculations. Discussion that omits the trial name or uses different spellings may also be missing, so an unmentioned issue is not evidence of no concern.","Several podcast passages lack an identifiable speaker. Their views remain attached to the episode and cannot be assigned from its title or guest list.","Some named authors have no established clinical role in these sources; other professional descriptions come only from the source itself. Named or verified identity does not increase the truth or representativeness of a view.","Cross-trial comparisons, clinical impressions, hypotheses and questions are not head-to-head findings. MARIPOSA, FLAURA2 and MARIPOSA-2 observations remain attached to those studies and settings.","LASER301 CNS findings apply to the eligible asymptomatic or stable CNS population. The intracranial response-rate difference was numerical and not statistically significant, despite enthusiastic response-rate commentary.","The LASER301 primary publication's OS analysis was immature and not statistically significant. OS statements about MARIPOSA cannot establish a LASER301 OS benefit.","Reported approvals, reimbursement conditions, availability and prices are dated source accounts. Exact current country-specific indications and access are not established here.","Publication and post dates do not establish session dates, a change of mind, or disagreement between statements made in different settings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":2,"publication":2,"registry":2,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":18,"methods":2,"results":2},"count":22,"evidence_window":{"end":"2026-01-16","start":"2020-09-21"},"retrieval_snapshot":"2026-10-31T02:59:03.053690Z","timeline":[{"count":1,"week":"2020-W39"},{"count":5,"week":"2022-W48"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W36"},{"count":3,"week":"2023-W42"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2026-W03"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT04248829:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04248829:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04248829:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04248829:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04248829:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:37379502","quote_policy":"short_quote_link_out"},{"id":"pubmed:37865896","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fraujaa5htqy5foevaon4ccn-3lcbieefabk2v","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7106228145611018241","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4c06ab","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8b39e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1222865695219712005:d362d267-5f32-4965-8dcc-bfc88281b2e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1222908096512610305:5aeb39bc-0384-4ec3-bafd-119710afdc02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1307837309732007936:91730101-b461-4137-96cd-7f928abf7a55","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1582984236583092224:9936e8a3-2111-4bdf-8eba-051d431e48dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1598877596535902208:094effbe-f837-48d2-8f0f-21984564779f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1598877995313561600:fca603a5-03d4-46cc-91cb-7daf991b50ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1598881418280861696:27c8e5da-7c8f-4459-9cc2-91a03ec2771a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1599066119842959360:a96ec5bf-384c-460f-a515-b3ea6215a325","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1599116655593857024:657ebfd9-1639-4b1c-8aeb-49f496950ed2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1674318015976931328:a5bf519e-4455-4e4b-af78-8f4e1dd8cc08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1674622682581676033:78a6c79e-ee2e-4bf4-a637-9289dc4f3a11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1676278583587897344:c71ff63d-0683-4744-9f39-a47543d16b51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678261619313221632:3016f2eb-d45b-4568-bff6-23b25d2f5b9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682028905644048390:1d1a162a-a88b-4602-96b2-67744306dad9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1683577819547279361:e61f07d9-52cb-4b41-a52d-1b671ebbf27c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1683598214640074752:b776b6d6-eb15-4486-9785-2384cfa4541f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1683779449018372098:dc4c3c78-abe0-4562-ab04-535698b45af4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701173832168407471:d72af7cb-8c15-4a8c-a532-18536bfcf9f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702266921482121686:ca1a7666-d955-4aed-aa53-e4ea9e22d4fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1702442455994614070:c719b457-cad5-4aee-8bda-3db0e1ff13fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1710414638221770968:2a800493-2ca1-408f-8589-5b684cd30095","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715963693781922064:505b072a-d373-4f2c-9f9f-caf019f1e98a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715982615084155265:8c320134-6812-48c7-ad14-395a05da6d19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715991228687204655:d4ad9b50-8132-440d-b5c4-275f997684a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715991336308838729:edc93b74-92db-482e-bae8-01a861e22621","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715994727869247809:ee9041c3-5a42-4b0c-b391-557f06ac96d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716031196566802628:6796455a-1ffe-4053-90c4-3813163b9ad0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716079114220921190:9d1cd688-a54a-41ea-b1ae-119fec800338","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716166300962361640:cc6938d8-e318-42a6-93bb-97960afa8545","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1728141522393043117:53f64904-4783-4dfe-b0f4-30daedd3ef24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1730427942873034920:5598dc60-6806-4fa6-a2f5-db9478d087b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784516188279550186:6df42aac-7d9d-4e09-ad8f-3b0afc6e4b6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1832844909616967959:6e2542a2-8c1d-49d3-8de3-7860e87a3206","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1862560804190539888:0d06c25e-be57-4161-95f6-1b4041c841c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1863324093593849878:a51a5342-273f-4005-8561-426fc5dc857e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911829960098001029:d51d26fc-938c-492f-9eff-d8f90b46bfe3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915893005694939234:51d8fb6f-435e-4846-9bb8-0242b156ae9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918010010883313881:53daa257-8f6e-44ab-80c4-4f41bf51f372","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1921249017997992299:7749f14c-6f24-4c4f-9701-e8b14eccffa2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963457656221294776:e4881bba-3942-466f-bdaf-3b4f18cc231f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970103319218831694:dd902b55-fc3c-468d-9a13-3320623d7d4b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011987762883465535:c6ee0837-9ed0-4a7e-a4c8-2f1363917550","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097231967037071739:ee1d080d-e502-4f6f-a775-eb41f709cca9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097447866814140839:f99ca3e3-86df-4fad-9974-7e71b0fcbdff","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":44,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":48},"count":48,"evidence_window":{"end":"2026-09-08","start":"2020-01-30"},"retrieval_snapshot":"2026-10-31T02:59:03.053690Z","timeline":[{"count":2,"week":"2020-W05"},{"count":1,"week":"2020-W39"},{"count":1,"week":"2022-W42"},{"count":5,"week":"2022-W48"},{"count":2,"week":"2023-W26"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W29"},{"count":3,"week":"2023-W30"},{"count":1,"week":"2023-W36"},{"count":3,"week":"2023-W37"},{"count":1,"week":"2023-W40"},{"count":8,"week":"2023-W42"},{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W48"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W36"},{"count":3,"week":"2024-W48"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W19"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2026-W03"},{"count":2,"week":"2026-W37"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Lazcluze"],"label":"lazertinib","slug":"lazertinib"},{"reason":"Unmapped registry intervention: gefitinib 250 mg","status":"unmapped"},{"reason":"Unmapped registry intervention: lazertinib-matching placebo 240 mg/160 mg","status":"unmapped"},{"reason":"Unmapped registry intervention: gefitinib-matching placebo 250 mg","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LASER301","aliases":["LASER301","Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"brief_title":"Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"display_condition":"first-line EGFR-mutated locally advanced or metastatic NSCLC","display_interventions":[["lazertinib"]],"enrollment":{"count":393,"type":"ACTUAL"},"interventions":[{"name":"Lazertinib 240 mg/160 mg","synonyms":["YH25448 240 mg/160 mg"],"type":"DRUG"},{"name":"Gefitinib 250 mg","synonyms":["Iressa 250 mg"],"type":"DRUG"},{"name":"Lazertinib-matching placebo 240 mg/160 mg","synonyms":["YH25448-matching placebo 240 mg/160 mg"],"type":"DRUG"},{"name":"Gefitinib-matching placebo 250 mg","synonyms":["Iressa-matching placebo 250 mg"],"type":"DRUG"}],"nct_id":"NCT04248829","official_title":"A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2022-07-29","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS was defined as the time from randomization until the date of objective progression or death(by any cause whichever comes first based on investigator assessment using RECIST v1.1 and was used to assess the efficacy of lazertinib compared to the gefitinib).","measure":"Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment","timeFrame":"At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant."}],"registered_date":{"date":"2020-01-30","type":"ACTUAL"},"registry_last_updated":"2026-06-29","registry_url":"https://clinicaltrials.gov/study/NCT04248829","short_name":"LASER301","short_name_basis":"canonical_name","sponsor":"Yuhan Corporation","start_date":{"date":"2020-02-13","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"YH25448-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}